Nonalcoholic fatty liver disease following liver transplantation

Hepatology International

Volumn 7, Issue 2, 2013, Pages 400-412

  Satapathy, Sanjaya Kumar ^a   Nair, Satheesh ^a   Vanatta, Jason M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Bariatric surgery; Cirrhosis; Liver transplantation; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Obesity; Vitamin E

Indexed keywords

ALANINE; CALCINEURIN INHIBITOR; INTERLEUKIN 6; LEPTIN; MALONALDEHYDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR; VERY LOW DENSITY LIPOPROTEIN;

BARIATRIC SURGERY; BODY MASS; DISEASE PREDISPOSITION; FATTY LIVER; GENETIC PREDISPOSITION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; LIPID METABOLISM; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 84876456720     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-013-9434-3     Document Type: Review

References (138)

1. Saadeh S. Nonalcoholic fatty liver disease and obesity. Nutr Clin Pract 2007;22:1-10
2. Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl 2006;12:523-534
3. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048-1058
4. Futagawa Y, Terasaki PI. An analysis of the OPTN/UNOS Liver Transplant Registry. Clin Transpl 2004;315-329
5. Cattral MS, Lilly LB, Levy GA. Immunosuppression in liver transplantation. Semin Liver Dis 2000;20:523-531
6. Burke A, Lucey MR. Non-alcoholic fatty liver disease, nonalcoholic steatohepatitis and orthotopic liver transplantation. Am J Transpl 2004;4:686-693
7. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transpl 2002;2:807-818
8. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006;6:1578-1585
9. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011;343:d6891
10. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-967
11. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10
12. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-79
13. Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H, Ohba K, Isomoto H, Mizuta Y, Hayashida K, Murase K, Kadota T, Murata I, Kohno S. Fatty liver in non-alcoholic nonoverweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 2002;17(10):1098-1105
14. Ground KE. Liver pathology in aircrew. Aviat Space Environ Med 1982;53:14-18
15. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a ‘normal’ population-examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977;12:593-597
16. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:142-149
17. Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH, Li JQ, Chen SY. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003;9:1106-1110
18. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40(6):1387-1395
19. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006;45(4):600-606
20. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29: 664-669
21. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32:689-692
22. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141(4):1249-1253
23. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-138
24. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44: 865-873
25. O’Leary JG, Landaverde C, Jennings L, Goldstein RM, Davis GL. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol 2011;9(8):700.e1-704.e1
26. Donnelly KL, Smith CJ, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351
27. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008;134:424-431
28. Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, Endo H, Takahashi H, Inamori M, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A. Dysfunctional very-lowdensity lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 2009;50 (3):772-780
29. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11(2):183-190
30. Wei Y, Clark SE, Morris EM, Thyfault JP, Uptergrove GM, Whaley-Connell AT, Ferrario CM, Sowers JR, Ibdah JA. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 2008;49(3):417-428
31. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008;103:1372-139
32. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996;274:1185-1188
33. Marra F. Leptin and liver fibrosis: a matter of fat. Gastroenterology 2002;122:1529-1532
34. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, Sato N. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001;34(2):288-297
35. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007;132:2169-2180
36. Nieto N. Oxidative-stress and IL-6 mediate the fibrogenic effects of Kupffer cells on stellate cells. Hepatology 2006;44: 1487-1501
37. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Investig 2003;112: 91-100
38. Diehl AM. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002;282:G1-G5
39. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96(5):1723-1732
40. Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 1998;4:285-296
41. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, Nashan B, Peltekian KM. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007;13(8):1109-1114
42. Modan-Moses D, Paret G. Leptin and transplantation: pieces are still missing in the puzzle. Isr Med Assoc J 2002;4:207-208
43. Man K, Zhao Y, Xu A, Lo CM, Lam KS, Ng KT, Ho JW, Sun CK, Lee TK, Li XL, Fan ST. Fat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival. Am J Transpl 2006;6(3):467-476
44. Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, Cioffi M, Ruggiero G, Adinolfi LE. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006;24 (9):1349-1357
45. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host-and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998;29(2):198-206
46. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW, Lane MD, Diehl AM. Leptin regulates proinflammatory immune responses. FASEB J 1998;12(1):57-65
47. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004;41(6): 943-949
48. Crespo J, Rivero M, Fabrega E, et al. Plasma leptin and TNFalpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci 2002;47:1604-1610
49. Piche T, Vandenbos F, Abakar-Mahamat A, et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 2004;11:91-96
50. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, Heimbach JK, Janssen HL, Charlton MR. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transpl 2009;9:1406-1413
51. Foxton MR, Quaglia A, Muiesan P, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transpl 2006;6:1922-1929
52. Trevisani F, Caraceni P, Simoncini M, Micati M, Domenicali M, Dazzani F, Zambruni A, Stefanelli C, Grazi G, Nardo B, Guarnieri C, Bernardi M. Evidence of oxidative imbalance in longterm liver transplant patients. Dig Liver Dis 2002;34:279-284
53. Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Papachristodoulou A, Kostakis AI. Correlation between oxidative stress and immunosuppressive therapy in renal transplant recipients with an uneventful postoperative course and stable renal function. Int Urol Nephrol 2006;38:343-348
54. Granot E, Elinav H, Kohen R. Markers of oxidative stress in cyclosporine-treated and tacrolimus-treated children after liver transplantation. Liver Transpl 2002;8:469-475
55. Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, Boillot O, Rubbia-Brandt L, Scoazec JY, Hadengue A. Non-alcoholic fatty liver disease in liver transplant recipients: another story of ‘‘seed and soil’’. Am J Gastroenterol 2010;105: 613-620
56. Marsman WA, Wiesner RH, Rodriguez L, Batts KP, Porayko MK, Hay JE, et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996;62(9):1246-1251
57. Selzner N, Selzner M, Jochum W, Amann-Vesti B, Graf R, Clavien PA. Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. J Hepatol 2006;44:694-701
58. Fishbein TM, Fiel MI, Emre S, Cubukcu O, Guy SR, Schwartz ME, Miller CM, Sheiner PA. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997;64: 248-251
59. Ureña MA, Ruiz-Delgado FC, González EM, Segurola CL, Romero CJ, García IG, González-Pinto I, Gómez Sanz R. Assessing risk of the use of livers with macro-and microsteatosis in a liver transplant program. Transpl Proc 1998;30: 3288-3291
60. D’Alessandro AM, Kalayoglu M, Sollinger HW, Hoffmann RM, Reed A, Knechtle SJ, Pirsch JD, Hafez GR, Lorentzen D, Belzer FO. The predictive value of donor liver biopsies on the development of primary nonfunction after orthotopic liver transplantation. Transpl Proc 1991;23:1536-1537
61. Ploeg RJ, D’Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et al. Risk factors for primary dysfunction after liver transplantation: a multivariate analysis. Transplantation 1993;55:807-813
62. Tevar AD, Clarke C, Wang J, Rudich SM, Woodle ES, Lentsch AB, et al. Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. J Am Coll Surg 2010;210:515-526
63. McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transpl 2006;6:1578-1585
64. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab 2006;32:539-546
65. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a metaanalysis of individual patient data. Gastroenterology 2006;130: 1636-1642
66. Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, Khettry U. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 2002;33: 1098-1104
67. Maor-Kendler Y, Batts KP, Burgart LJ, Wiesner RH, Krom RA, Rosen CB, Charlton MR. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation 2000;70: 292-297
68. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001;7:363-373
69. Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 1997;3:177-178
70. Cauble MS, Gilroy R, Sorrell MF, Mailliard ME, Sudan DL, Anderson JC, et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation 2001;71:892-895
71. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001;7(9):797-801
72. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, Rosen CB, Batts KP. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001;7:608-614
73. Lim LG, Cheng CL, Wee A, Lim SG, Lee YM, Sutedja DS, Da Costa M, Prabhakaran K, Wai CT. Prevalence and clinical associations of posttransplant fatty liver disease. Liver Int 2007; 27:76-80
74. Seo S, Maganti K, Khehra M, Ramsamooj R, Tsodikov A, Bowlus C, et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 2007;13:844-847
75. Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009;15: 1814-1820
76. Dureja P, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A. NAFLD recurrence in liver transplant recipients. Transplantation 2011;91(6):684-689
77. Duclos-Valée J-C, Yilmaz F, Johanet C, Roque-Afonso A-M, Gigou M, Trichet C, et al. Could post-liver transplantation course be helpful for the diagnosis of so-called cryptogenic cirrhosis? Clin Transpl 2005;19:591-599
78. Heringlake S, Schu¨ tte A, Flemming P, Schmiegel W, Manns MP, Tillmann HL. Presumed cryptogenic liver disease in Germany: high prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. Z Gastroenterol 2009;47:417-423
79. Henegan MA, Zolfino T, Muiesan P, Portmann BC, Rela M, Heaton ND, et al. An evaluation of long-term outcomes after liver transplantation for cryptogenic cirrhosis. Liver Transpl 2003;9:921-928
80. Poordad F, Gish R, Wakil A, et al. De novo non-alcoholic fatty liver disease following orthotopic liver transplantation. Am J Transpl 2003;3:1413-1417
81. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology 2010;51:373-375
82. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356-1362
83. Jiang J, Torok N. Nonalcoholic steatohepatitis and the metabolic syndrome. Metab Syndr Relat Disord 2008;6:1-7
84. Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009;49: 809-820
85. Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transpl 2009;9:782-793
86. Guckelberger O, Mutzke F, Glanemann M, et al. Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl 2006;12:394-401
87. Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract 2008;14(8):979-984
88. Demir E, Paydas S, Balal M, Kurt C, Sertdemir Y, Erken U. Effects of pentoxifylline on the cytokines that may play a role in rejection and resistive index in renal transplant recipients. Transpl Proc 2006;38(9):2883-2886
89. Shu KH, Wu MJ, Chen CH, Cheng CH, Lian JD, Lu YS. Effect of pentoxifylline on graft function of renal transplant recipients complicated with chronic allograft nephropathy. Clin Nephrol 2007;67(3):157-163
90. Briggs WA, Eustace J, Mathew S, Gimenez LF, Choi M, Scheel PJ Jr, Burdick J. Pentoxifylline potentiates in vitro lymphocyte suppression by glucocorticoids and immunosuppressive drugs. J Clin Pharmacol 1998;38(6):561-566
91. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, Wiesner RH. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007;13(9):1236-1245
92. Marmur J, Bergquist A, Stål P. Liver transplantation of patients with cryptogenic cirrhosis: clinical characteristics and outcome. Scand J Gastroenterol 2010;45:60-69
93. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116: 1413-1419
94. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27: 103-107
95. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003;348: 2082-2090
96. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360:859-873
97. Erlichman J, Kerbey AL, James WP. Physical activity and its impact on health outcomes. Paper 2. Prevention of unhealthy weight gain and obesity by physical activity: an analysis of the evidence. Obes Rev 2002;3:273-287
98. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192
99. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-1184
100. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307
101. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46:424-429
102. Balas B, Belfort R, Harrison SA, Darland C, Finch J, Schenker S, Gastaldelli A, Cusi K. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol 2007;47:565-570
103. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-39
104. Lago RM, Singh PP, Nesto R. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-1136
105. US Food and Drug Administration Center for Drug Evaluation and Research. Post market Drug Safety Information for Patients and Providers: pioglitazone HCl (marketed as Actos, ActoplusMet, and Duetact). Rockville: FDA, 2007. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109136.htm. Accessed on 07 Jan 2010
106. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471
107. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al. LIDO Study Group. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010;51:445-453
108. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46
109. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA 2008;300:2123-2133
110. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007;(1):CD005166
111. Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation? Am J Transpl 2011;11(7):1376-1381
112. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010;55:560-578
113. Fiqueiredo FA, Dickson ER, Pasha TM, Porayko MK, Therneau TM, Malinchoc M, et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with endstage liver disease. Liver Transpl 2000;6:575-581
114. Braunfeld MY, Chan S, Pregler J, Neelakanta G, Sopher MJ, Busuttil RW, Csete M. Liver transplantation in the morbidly obese. J Clin Anesth 1996;8:585-590
115. Hillingso JG, Wettergren A, Hyoudo M, Kirkegaard P. Obesity increases mortality in liver transplantation: the Danish experience. Transpl Int 2005;18:1231-1235
116. Nair S, Cohen DB, Cohen MP, Tan H, Maley W, Thuluvath PJ. Postoperative morbidity, mortality, costs, and long-term survival in severely obese patients undergoing orthotopic liver transplantation. Am J Gastroenterol 2001;96:842-845
117. Sawyer RG, Pelletier SJ, Pruett TL. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. Clin Transpl 1999;13:126-130
118. Keeffe EB, Gettys C, Esquivel CO. Liver transplantation in patients with severe obesity. Transplantation 1994;57:309-311
119. Schaeffer DF, Yoshida EM, Buczkowski AK, Chung SW, Steinbrecher UP, Erb SE, Scudamore CH. Surgical morbidity in severely obese liver transplant recipient: a single Canadian center experience. Ann Hepatol 2009;8:38-40
120. Selberg O, Bottcher J, Tusch G, Pichlmayr R, Henkel E, Muller MJ. Identification of high-and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology 1997;25: 652-657
121. Stephenson GR, Moretto EW, El-Moalem H, Clavien PA, Tuttle-Newhall JE. Malnutrition in liver transplant patients: preoperative subjective global assessment is predictive of outcome after liver transplantation. Transplantation 2001;72:666-670
122. Bilbao J, Armadan L, Lazaro JL, Hidalgo E, Castells L, Marqarit C. Predictive factors for early mortality following liver transplantation. Clin Transpl 2003;17:1401-1411
123. Hade AM, Shine AM, Kennedy NP, McCormick PA. Both under-nutrition and obesity increase morbidity following liver transplantation. Ir Med J 2003;96:140-142
124. Merli M, Nicolini G, Angeloni S, Riqqio O. Malnutrition is a risk factor in cirrhotic patients undergoing surgery. Nutrition 2002;18:978-986
125. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology. 2002;35:105-109
126. Leonard J, Heimbach JK, Malinchoc M, Watt K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transpl 2008;8:667-672
127. Duchini A, Brunson ME. Roux-en-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity. Transplantation 2001;72:156-159
128. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, Montgomery RA, Cameron AM, Maley WR. Steroid avoidance in liver transplantation: meta-analysis and metaregression of randomized trials. Liver Transpl 2008;14:512-525
129. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, Nashan B, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007;13:1109-1114
130. Tueche SG. Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. Transpl Proc 2003;35 (4):1466-1468
131. Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, Eckhoff DE, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(?) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007;13:1521-1531
132. Houlihan D, Armstrong M, Davidov Y, Hodson J, Nightingale P, Rowe I, Paris S, Gunson B, Bramhall S, Mutimer D, Neuberger J, Newsome P. Renal function in patients transplanted for NASH cirrhosis: time to reconsider immunosuppression regimens? Liver Transpl 2011;17(11):1292-1298. doi:10.1002/lt.22382
133. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465
134. Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, Zhang W, Vollenweider P, Stirnadel H, Johnson T, Bergmann S, Beckmann ND, Li Y, Ferrucci L, Melzer D, Hernandez D, Singleton A, Scott J, Elliott P, Waeber G, Cardon L, Frayling TM, Kooner JS, Mooser V. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008;83:520-528
135. Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009;50:2111-2116
136. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstråle M, Groop L, Orho-Melander M, Yki-Järvinen H. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009;137: 865-872
137. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148 M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-1217
138. Romeo S, Sentinelli F, Cambuli VM, Incani M, Congiu T, Matta V, Pilia S, HuangDoran I, Cossu E, Loche S, Baroni MG. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010;53(2):335-338